Abstract
Summary: Monoclonal antibodies (mAbs) are used as therapeutics in a number of disciplines in medicine, such as oncology, rheumatology, gastroenterology, dermatology and transplant rejection prevention. Since the introduction and reintroduction of the anti-alpha4-integrin mAb natalizumab in 2004 and 2006, mAbs have gained relevance in the treatment of multiple sclerosis (MS). At present, numerous mAbs have been tested in clinical trials in relapsing-remitting MS, and in progressive forms of MS. One of the agents that might soon be approved for very active forms of relapsing-remitting MS is alemtuzumab, a humanized mAb against CD52. This review provides insights into clinical studies with the mAbs natalizumab, alemtuzumab, daclizumab, rituximab, ocrelizumab and ofatumumab.
Original language | English (US) |
---|---|
Pages (from-to) | 373-384 |
Number of pages | 12 |
Journal | Clinical and Experimental Immunology |
Volume | 175 |
Issue number | 3 |
DOIs | |
State | Published - Mar 2014 |
Keywords
- Alemtuzumab
- Daclizumab
- Multiple sclerosis
- Natalizumab
- Rituximab
ASJC Scopus subject areas
- Immunology and Allergy
- Immunology